![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/f/fa/Taranabant_3D_spacefill.png/640px-Taranabant_3D_spacefill.png&w=640&q=50)
Taranabant
Chemical compound / From Wikipedia, the free encyclopedia
Taranabant (codenamed MK-0364) is a cannabinoid receptor type 1 (CB1) inverse agonist that was investigated as a potential treatment for obesity due to its anorectic effects.[1][2] It was discovered by Merck & Co.
Quick Facts Clinical data, Routes ofadministration ...
![]() | |
![]() | |
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.207.983 ![]() |
Chemical and physical data | |
Formula | C27H25ClF3N3O2 |
Molar mass | 515.96 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Close
In October 2008, Merck has stopped its phase III clinical trials with the drugs due to high level of central nervous system side effects, mainly depression and anxiety.[3][4][5][6]